Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review

Objective: The incidence of immune-related adverse events is growing as the use of checkpoint inhibitors is exponentially increasing. Cutaneous adverse events are among the most frequent immune-related adverse events. The purpose of this case report and literature review is to highlight psoriasis as...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Case reports in dermatology Ročník 10; číslo 2; s. 190 - 197
Hlavní autoři: De Bock, Marlies, Hulstaert, Eva, Kruse, Vibeke, Brochez, Lieve
Médium: Journal Article
Jazyk:angličtina
Vydáno: Basel, Switzerland S. Karger AG 01.05.2018
Karger Publishers
Témata:
Anti-PD-1
Anti-PDL-1
Apoptosis
Case and Review
Case reports
Checkpoint inhibitors
Immune-related adverse events
Immunotherapy
Literature reviews
Lung cancer
Melanoma
Metastasis
Monoclonal antibodies
Patients
Psoriasis
Rheumatology
Skin
Targeted cancer therapy
Checkpoint inhibitors
Anti-PD-1
Immune-related adverse events
Psoriasis
Anti-PDL-1
ISSN:1662-6567, 1662-6567
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Objective: The incidence of immune-related adverse events is growing as the use of checkpoint inhibitors is exponentially increasing. Cutaneous adverse events are among the most frequent immune-related adverse events. The purpose of this case report and literature review is to highlight psoriasis as a potential adverse event with need for early recognition. Case Report and Literature Review: We describe the case of a 65-year-old woman with psoriasis exacerbation while treated with nivolumab (anti-PD-1) for a stage IV melanoma. She had a history of scalp psoriasis but she presented with psoriatic lesions on both lower and upper limbs. Our patient was treated with topical steroids. So far, 34 other cases with an exacerbation of psoriasis during treatment with anti-PDL-1 or PD-1 therapy have been reported in the literature. A broad range of therapies are described, without any available guidelines for this particular condition. Conclusion: Psoriasis exacerbation is an established side effect of PD-1/PDL-1 checkpoint inhibitors with 35 reported cases. Early recognition and management are challenging as there are no clear guidelines available. A close collaboration between oncologist and dermatologist is mandatory to manage this immune-related adverse event.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Report-3
ObjectType-Case Study-4
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1662-6567
1662-6567
DOI:10.1159/000491572